Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib ... for severe alopecia areata (AA).

Baricitinib, a Janus kinase (JAK) inhibitor, combined with narrowband ultraviolet B (UVB) phototherapy, reduced disease activity and improved repigmentation and quality of life in adults with ...